Islet autoantibodies and insulin dependent diabetes mellitus in cystic fibrosis

Journal of Pediatric Endocrinology and Metabolism

Volumn 13, Issue 3, 2000, Pages 319-324

  Nousia Arvanitakis, Sanda ^a   Galli Tsinopoulou, Assimina ^b   Dracoulacos, Dracoulis ^b   Karamouzis, Michael ^b   Demitriadou, Aphrodite ^b  

^a Pediatric Gastroenterology   (Greece)

^b NONE

Author keywords

Cystic fibrosis; FPIR; GAD; IA 2; Islet autoantibodies

Indexed keywords

AUTOANTIBODY; GLUTAMATE DECARBOXYLASE; INSULIN;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ARTICLE; CELL DESTRUCTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESPONSE; MALE; PANCREAS ISLET BETA CELL;

EID: 0034066277     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2000.13.3.319     Document Type: Article

References (36)

1. Rosan R, Schwachman H, Kulczycki L. Diabetes mellitus and cystic fibrosis of the pancreas. Am J Dis Child 1962; 104: 625-634.
2. Lanng S, Thorsteinsson B, Erichson G, Nerup J, Koch C. Glucose tolerance in cystic fibrosis. Arch Dis Child 1991; 66: 612-616.
3. Geffner ME, Lippe BM, Kaplan SA. Carbohydrate tolerance in cystic fibrosis is closely linked to pancreatic exocrine function. Pediatr Res 1984; 18: 1107-1111.
4. Kopelman H, Corey M, Gaskin K, Durie P, Weizman ZU, Forstner G. Impaired chloride secretion, as well as bicarbonate secretion, underlies the fluid secretory defect in the cystic fibrosis pancreas. Gastroenterology 1988; 95: 349-355.
5. Handwerger S, Roth J, Gordern P, Di Sant'Agnesi P, Carpenter DF, Peter G. Glucose intolerance in cystic fibrosis. N Engl J Med 1969; 281: 451-461.
6. Nousia-Arvanitakis S, Tomita T, Desai N, Kimmel JR. Pancreatic polypeptide in cystic fibrosis. Arch Pathol Lab Med 1985; 109: 722-726.
7. De Luca F, Arrigo T, Di Benedetto A, Tedeschi A, Sferlazzas C, Crisafulli G, Di Cesare E, Romano G, Magazzu G, Cucinotta D. Four year follow-up of glucose tolerance and beta-cell function in nondiabetic cystic fibrosis patients. Horm Res 1995; 44: 45-50.
8. Nousia-Arvanitakis S, Karagiozoglou-Lampoudes T, Galli-Tsinopoulou A, Augoustidou-Savopoulou P, Salem N, Stephanides A. Influence of exocrine pancreas on beta-cell function in cystic fibrosis. Hell J Gastroenterol 1995; 8: 136-140.
9. Krueger LJ, Lerner A, Katz SM, Mack R, Holsclaw DS, Lebenthal E. Cystic fibrosis and diabetes mellitus: interactive or idiopathic? J Pediatr Gastroenterol Nutr 1991; 13: 209-219.
10. Erdo SL, Wolff JR. Gamma-Aminobutyric acid outside the mammalian brain. J Neurochem 1990; 54: 363-372.
11. Clare-Slazer M, Tobin A, Kaufman D. Glutamate decarboxylase: an autoantigen in IDDM. Diabetes Care 1992; 15: 132-135.
12. Rabin DU, Rae PM. Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatase. J Immunol 1994; 152: 3183-3188.
13. Lampasona V, Bearzatto M, Genovese S, Bosi E, Ferrari M, Bonifacio E. Autoantibodies in insulin-dependent diabetes recognize distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen. J Immunol 1996; 157: 2707-2711.
14. Áanstoot HJ, Sigurdsson E, Jaffe M, Shi Y, Christgau S, Grobbee D, Bruining GJ, Molenaar JL, Hofman A, Baekkeskov S. Value of antibodies to GAD 65 combined with islet cell cytoplasmic antibodies for predicting IDDM in a childhood population. Diabetologia 1994; 37: 917-924.
15. Skyler JS. Prediction and prevention of type 1 diabetes mellitus. Topical Endocrinol 1998; 10: 6-9.
16. Srikanta S, Ganda OP, Gleason RE, Jackson RA, Soeldner JS, Eisenbarth GS. Pre type I diabetes linear loss of beta cell response to intravenous glucose. Diabetes 1984; 33: 717-720.
17. th Ed. Philadelphia, PA: Lea and Febinger, 1985; 332-352.
18. Defronzo R, Tobin J, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: 214-223.
19. Peraldo M, Fasulo A, Chiappini E, Milio C, Marianelli L. Evaluation of glucose tolerance and insulin secretion in cystic fibrosis patients. Horm Res 1998; 49: 65-71.
20. Rosenecker J, Eichler I, Kuhn L, Harms HK, von der Hardt H. Genetic determination of diabetes mellitus in patients with cystic fibrosis: Multicenter cystic fibrosis study group. J Pediatr 1995; 127: 441-443.
21. Holl RW, Wolf A, Thon A, Bernhard M, Buck C, Missel M, Heinze E, von der Hardt H, Teller WM. Insulin resistance with altered secretory kinetics and reduced proinsulin in cystic fibrosis patients. J Pediatr Gastrenterol Nutr 1997; 25: 188-193.
22. Stutchfield PR, O'Halloran SM, Smith CS, Woodrow JC, Bottazzo GF, Heaf D. HLA type, islet cell antibodies and glucose intolerance in cystic fibrosis. Arch Dis Child 1988; 63: 1234-1239.
23. Eisenbarth GS, Rewers M. Editorial: Refining genetic analysis of type 1 diabetes. J Clin Endocrinol Metab 1995; 80: 2564-2566.
24. Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA. The role of HLA class II genes in insulin dependent diabetes mellitus. Molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet 1996; 59: 1134-1148.
25. Todd JA, Bell JI, McDevitt HO, HLA-DQ beta gene contributes to susceptibility and resistance to insulin dependent diabetes mellitus. Nature (Lond) 1987; 329: 599-604.
26. Robert JJ, Grasset E, De Montalembart M, Chevenne D, Deschamps I, Boitard C, Lenoir G. Research of factors for glucose intolerance in mucoviscidosis. Arch Pediatr 1992; 49: 17-22.
27. Ferrari M, Cremonesi L. Genotype-phenotype correlation in cystic fibrosis patients. Ann Biol Clin 1996; 54: 235-241.
28. Nousia-Arvanitakis S, Balasopoulou A, Agguridaki C, Mavrovouniotis C, Augustidou P, Galli-Tsinopoulou K. Correlation of exocrine pancreatic function and genotype in cystic fibrosis. Gut 1997; 41 : A244 (abst).
29. De Aizpura HJ, Harrison LC, Cram DS. An ELISA for antibodies to recombinant glutamic acid deacarboxylase in IDDM. Diabetes 1992; 41: 1182-1187.
30. Schmidli RS, Colman PG, Bonifacio E. Disease sensitivity and specificity of 52 assays for glutamic acid decarboxylase antibodies. The Second International GADAB Workshop. Diabetes 1995; 44: 636-640.
31. Baron EJ, Weber DE, Weide LG. Lack of agreement among two commmercial enzyme-linked immunosorbent antibody assays and a conventional immunofluorescence-based method for detecting islet cell autoantibodies. Clin Diagn Lab Immunol 1996; 3: 429-431.
32. Pfutzner A, Forst T, Ambrosch A, Schmitz H, Lichtwald K, Beyer J. Determination of anti GAD65 autoantibodies with ELISA before and after standarization with the new international reference serum. Exp Clin Endocrinol Diabetes 1995; 103: 123-125.
33. Verge CF, Stenger D, Bonifacio E, Colman PG, Pilcher C, Bingley PJ, Eisenbarth GS. Combined use of autoantibodies (1A-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type I diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 1998; 47: 1857-1866.
34. Seissler J, Morgenthaler NG, Achenbach P, Lampeter EF, Glawe D, Payton M, Christie M, Scherbaum WA. Combined screening for autoantibodies to IA-2 and antibodies to glutamic acid decarboxylase in first degree relatives of patients with IDDM. The DENIS Study Group. Deutsche Nicotinamid Interventions-Studie. Diabetologia 1996; 39: 1351-1356.
35. Lernmark A, Kolb H, Mire-Sluis T. Towards a World Health Organization (WHO) approved standard sample for islet cell antibodies, GAD65 and IA-2 autoantibodies. Diabetologia 1999; 42: 381-382.
36. Brown JC, Otte SC. Gastrointestinal hormones and the control of insulin secretion. Diabetes 1978; 27: 182-186.